{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-25-000059","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.092262+00:00","generated_at":"2026-05-17T22:25:57.827449+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"LENZ Therapeutics receives FDA approval for VIZZ (aceclidine) to treat presbyopia","bullets":["VIZZ (aceclidine ophthalmic solution) 1.44% approved by FDA for presbyopia, impacting ~128M US adults.","First and only aceclidine-based eye drop; once-daily dosing with proven efficacy up to 10 hours.","Samples and commercial availability expected as early as October 2025; sales activities to begin immediately.","Approval based on three Phase 3 studies (CLARITY 1,2,3) showing rapid onset within 30 min and consistent near-vision improvement.","Well-tolerated; most common adverse reactions were instillation site irritation, dim vision, headache, mostly mild and self-resolving."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-25-000059","json":"https://secwatch.observer/filing/0001815776-25-000059.json","markdown":"https://secwatch.observer/filing/0001815776-25-000059.md","text":"https://secwatch.observer/filing/0001815776-25-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000059/0001815776-25-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000059/lenz-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:25:57.827449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}